{
    "nct_id": "NCT04092764",
    "official_title": "Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN) Using a Point-Of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork",
    "inclusion_criteria": "* Must have undergone chemotherapy with taxane and/or platinum agent\n* Presence of numbness, paresthesias, loss of deep tendon reflexes, or other symptoms in the lower extremities those were absent prior to treatment with neurotoxic chemotherapy.\n* Three or more months status post platinum containing chemotherapy completion\n* Grade â‰¥1 Level of CIPN that is determined by the NCI Common Toxicity Criteria for Adverse Events.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Peripheral neuropathy from causes other than chemotherapy, such as documented\n* a. Nerve compression (carpal tunnel syndrome, sciatica, etc)\n* b. Previously known leptomeningeal carcinomatosis\n* c. Evidence of disease in the brain or spine by prior imaging\n* Comorbidities with documented pre-existing neuropathy prior to the chemotherapy such as\n* a. Diabetes (HbA1c 6.5% or greater)\n* b. HIV\n* c. Multiple myeloma\n* d. Alcoholism\n* Pain medication dosing, including opioids, anti-convulsants, and anti- depressantshas been increased due to worsening symptoms less than in the two weeks prior to study registration\n* Current use of acupuncture (manual or electro acupuncture)\n* Pregnancy\n* Cardiac issues (AHA class 3 or greater)\n* Pacemaker or an imbedded neural stimulator\n* Full therapeutic anticoagulation or a INR > 1.4\n* Currently undergoing chemotherapy with a platinum agent or have received a platinum chemotherapy agent in the past 3 months.",
    "miscellaneous_criteria": ""
}